Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease

As the prevalence of diabetic kidney disease (DKD) continues to rise, so does the need for a novel therapeutic modality that can control and slow its progression to end-stage renal disease. The advent of sodium-glucose cotransporter-2 (SGLT2) inhibitors has provided a major advancement for the treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaffner, James, Chen, Bohan, Malhotra, Deepak K., Dworkin, Lance D., Gong, Rujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591164/
https://www.ncbi.nlm.nih.gov/pubmed/34790170
http://dx.doi.org/10.3389/fendo.2021.749010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591164/
https://www.ncbi.nlm.nih.gov/pubmed/34790170
http://dx.doi.org/10.3389/fendo.2021.749010

Ejemplares similares